Braveheart Bio Prices Upsized $18 IPO, Set to List on Nasdaq Aug. 6

Braveheart Bio Inc., a clinical‑stage biopharmaceutical company developing next‑generation therapeutics for hypertrophic cardiomyopathy and other serious cardiovascular diseases, announced the pricing of an upsized initial public offering of 21,250,000 common shares at $18.00 per share. The offering includes a 30‑day underwriter option to purchase an additional 3,187,500 shares at the same price.

The gross proceeds are expected to be about $382.5 million before underwriting discounts and expenses. Joint book‑running managers are Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor. Registration statements became effective on August 5, 2026, and the shares are slated to begin trading on the Nasdaq Global Market under the ticker “BRVE” on August 6, 2026, with the offering expected to close on August 7, 2026, subject to customary conditions.